EP1007708A1 - Inhibition de l'expression de l'enzyme ramifiante de l'amidon par un intron sens - Google Patents

Inhibition de l'expression de l'enzyme ramifiante de l'amidon par un intron sens

Info

Publication number
EP1007708A1
EP1007708A1 EP98904329A EP98904329A EP1007708A1 EP 1007708 A1 EP1007708 A1 EP 1007708A1 EP 98904329 A EP98904329 A EP 98904329A EP 98904329 A EP98904329 A EP 98904329A EP 1007708 A1 EP1007708 A1 EP 1007708A1
Authority
EP
European Patent Office
Prior art keywords
sequence
nucleotide sequence
intron
sense
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98904329A
Other languages
German (de)
English (en)
Inventor
Peter Poulsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DuPont Nutrition Biosciences ApS
Danisco US Inc
Original Assignee
Danisco AS
Danisco US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9703672.7A external-priority patent/GB9703672D0/en
Priority claimed from GBGB9706075.0A external-priority patent/GB9706075D0/en
Application filed by Danisco AS, Danisco US Inc filed Critical Danisco AS
Publication of EP1007708A1 publication Critical patent/EP1007708A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C12N9/107—1,4-Alpha-glucan branching enzyme (2.4.1.18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C12N15/8245—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis

Definitions

  • the present invention relates to a method of inhibiting gene expression, particularly inhibiting gene expression in a plant.
  • the present invention also relates to a nucleotide sequence useful in the method.
  • the present invention relates to a promoter that is useful for expressing the nucleotide sequence.
  • Starch is one of the main storage carbohydrates in plants, especially higher plants.
  • the structure of starch consists of amylose and amylopectin.
  • Amylose consists essentially of straight chains of ⁇ -l-4-linked glycosyl residues.
  • Amylopectin comprises chains of ⁇ -l-4-linked glycosyl residues with some ⁇ -1-6 branches.
  • the branched nature of amylopectin is accomplished by the action of inter alia an enzyme commonly known as the starch branching enzyme ("SBE").
  • SBE catalyses the formation of branch points in the amylopectin molecule by adding ⁇ -1,4 glucans through ⁇ -l,6-glucosidic branching linkages.
  • the biosynthesis of amylose and amylopectin is schematically shown in Figure 1, whereas the ⁇ -l-4-links and the ⁇ -1-6 links are shown in Figure 2.
  • starch is an important raw material. Starch is widely used in the food, paper, and chemical industries. However, a large fraction of the starches used in these industrial applications are post-harvest modified by chemical, physical or enzymatic methods in order to obtain starches with certain required functional properties.
  • WO96/34968 discusses the use of antisense sequences complementary to sequences which encode class A and class B potato SBE to downregulate SBE expression in potato plants.
  • the sequences used are complementary to SBE coding sequences.
  • a method of affecting enzymatic activity in a plant comprising expressing in the plant (or a cell, a tissue or an organ thereof) a nucleotide sequence wherein the nucleotide sequence partially or completely codes (is) an intron of the potato class A SBE gene in a sense orientation, optionally together with a nucleotide sequence which codes, partially or completely, for an intron of a class B starch branching enzyme in a sense or antisense orientation; and wherein the nucleotide sequence does not contain a sequence that is a sense exon sequence normally associated with the intron.
  • a method of affecting enzymatic activity in a starch producing organism comprising expressing in the starch producing organism (or a cell, a tissue or an organ thereof) a nucleotide sequence wherein the nucleotide sequence codes, partially or completely, for an intron of the potato class A SBE gene in a sense orientation optionally together with a nucleotide sequence which codes, partially or completely, for an intron of a class B starch branching enzyme in a sense or antisense orientation; wherein the nucleotide sequence does not contain a sequence that is sense to an exon sequence normally associated with the intron; and wherein starch branching enzyme activity is affected and/or the levels of amylopectin are affected and/or the composition of starch is changed.
  • the class A SBE gene sense intron construct is used in combination with a potato class B SBE gene sense intron construct as defined in PCT/EP96/03053.
  • it may also be used independently thereof, to target class A SBE alone, or in combination with other transgenes such as other sense and/or antisense transgenes, for example antisense intron transgenes such as from SBE genes, to further manipulate starch quality in potato plants.
  • a sequence comprising the nucleotide sequence shown as SEQ. ID. No. 38 or a variant, derivative or homologue thereof.
  • a promoter comprising the sequence shown as SEQ.I.D. No. 14 or a variant, derivative or homologue thereof.
  • a construct capable of comprising or expressing the present invention.
  • a vector comprising or expressing the present invention.
  • a seventh aspect of the present invention there is provided a cell, tissue or organ comprising or expressing the present invention.
  • a transgenic starch producing organism comprising or expressing the present invention.
  • a starch obtained from the present invention is provided.
  • a key advantage of the present invention is that it provides a method for preparing modified starches that is not dependent on the need for post-harvest modification of starches. Thus the method of the present invention obviates the need for the use of hazardous chemicals that are normally used in the post-harvest modification of starches.
  • the present invention provides ter alia genetically modified plants which are capable of producing modified and/or novel and/or improved starches whose properties would satisfy various industrial requirements.
  • the present invention provides a method of preparing tailor-made starches in plants which could replace the post-harvest modified starches.
  • the present invention provides a method that enables modified starches to be prepared by a method that can have a more beneficial effect on the environment than the known post-harvest modification methods which are dependent on the use of hazardous chemicals and large quantities of energy.
  • An other key advantage of the present invention is that it provides a method that may more reliably and/or more efficiently and/or more specifically affect enzymatic activity when compared to the known methods of affecting enzymatic activity.
  • this advantage of the present invention it is to be noted that there is some degree of homology between coding regions of SBEs. However, there is little or no homology with the intron sequences of SBEs. Thus, sense intron expression provides a mechanism to affect selectively the expression of a particular SBE.
  • This advantageous aspect could be used, for example, to reduce or eliminate a particular SBE enzyme and replace that enzyme with another enzyme which can be another branching enzyme or even a recombinant version of the affected enzyme or even a hybrid enzyme which could for example comprise part of a SBE enzyme from one source and at least a part of another SBE enzyme from another source.
  • Another enzyme which can be another branching enzyme or even a recombinant version of the affected enzyme or even a hybrid enzyme which could for example comprise part of a SBE enzyme from one source and at least a part of another SBE enzyme from another source.
  • the present invention provides a mechanism for selectively affecting SBE activity. This is in contrast to the prior art methods which are dependent on the use of for example antisense exon expression whereby it would not be possible to introduce new SBE activity without affecting that activity as well.
  • class B SBE is synonymous with SBE I: class A SBE is synonymous with SBE II.
  • Class A SBE is as defined in WO96/34968, incorporated herein by reference.
  • the antisense intron construct used comprises intron 1 of class A SBE, which is 2.0 kb in length and is located starting at residue 45 of the coding sequence of class A SBE.
  • the boundaries of the intron may be calculated by searching for consensus intron boundary sequences, and are shown in attached figure 11.
  • the sequence of the intron is set forth in SEQ. ID. No. 38.
  • Class B SBE is substantially as defined in the sequences given herein and in PCT/EP96/03053.
  • starch branching enzyme activity is affected and/or wherein the levels of amylopectin are affected and/or the composition of starch is changed.
  • the nucleotide sequence does not contain a sequence that is sense to an exon sequence.
  • the promoter is in combination with a gene of interest ("GOI").
  • GOI gene of interest
  • the enzymatic activity is reduced or eliminated.
  • the nucleotide sequence codes for at least substantially all of at least one intron in a sense orientation.
  • the nucleotide sequence codes, partially or completely, for two or more introns and wherein each intron is in a sense orientation.
  • the nucleotide sequence comprises at least 350 nucleotides (e.g. 350 bp), more preferably at least 500 nucleotides (e.g. 500 bp).
  • nucleotide sequence comprises the sequence shown as SEQ. ID. No. 38, or a fragment thereof.
  • nucleotide sequence is expressed by a promoter having a sequence shown as SEQ. I.D. No. 14 or a variant, derivative or homologue thereof.
  • the transgenic starch producing organism is a plant.
  • a preferred aspect of the present invention therefore relates to a method of affecting enzymatic activity in a plant (or a cell, a tissue or an organ thereof) comprising expressing in the plant (or a cell, a tissue or an organ thereof) a nucleotide sequence wherein the nucleotide sequence codes, partially or completely, for a class A SBE intron in a sense orientation; wherein the nucleotide sequence does not contain a sequence that is sense to an exon sequence normally associated with the intron; and wherein starch branching enzyme activity is affected and/or the levels of amylopectin are affected and/or the composition of starch is changed.
  • a more preferred aspect of the present invention therefore relates to a method of affecting enzymatic activity in a plant (or a cell, a tissue or an organ thereof) comprising expressing in the plant (or a cell, a tissue or an organ thereof) a nucleotide sequence wherein the nucleotide sequence codes, partially or completely, for an intron in a sense orientation; wherein the nucleotide sequence does not contain a sequence that is sense to an exon sequence normally associated with the intron; wherein starch branching enzyme activity is affected and/or the levels of amylopectin are affected and/or the composition of starch is changed; and wherein the nucleotide sequence comprises the sequence shown as SEQ. ID. No. 38, or fragments thereof.
  • nucleotide in relation to the present invention includes DNA and RNA.
  • DNA Preferably it means DNA, more preferably DNA prepared by use of recombinant DNA techniques.
  • intron is used in its normal sense as meaning a segment of nucleotides, usually DNA, that does not encode part or all of an expressed protein or enzyme.
  • exon is used in its normal sense as meaning a segment of nucleotides, usually DNA, encoding part or all of an expressed protein or enzyme.
  • the term “intron” refers to gene regions that are transcribed into RNA molecules, but which are spliced out of the RNA before the RNA is translated into a protein.
  • the term “exon” refers to gene regions that are transcribed into RNA and subsequently translated into proteins.
  • variant or “homologue” or “fragment” in relation to the nucleotide sequence of the present invention include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the respective nucleotide sequence providing the resultant nucleotide sequence can affect enzyme activity in a plant, or cell or tissue thereof, preferably wherein the resultant nucleotide sequence has at least the same effect as the sequence shown in SEQ. ID. No. 38.
  • homologue covers homology with respect to similarity of structure and/or similarity of function providing the resultant nucleotide sequence has the ability to affect enzymatic activity in accordance with the present invention.
  • sequence homology i.e. similarity
  • sequence homology preferably there is more than 80% homology, more preferably at least 85% homology, more preferably at least 90% homology, even more preferably at least 95% homology, more preferably at least 98% homology.
  • variant or variant or fragment in relation to the promoter of the present invention include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the respective promoter sequence providing the resultant promoter sequence allows expression of a GOI, preferably wherein the resultant promoter sequence has at least the same effect as SEQ. I.D. No. 14.
  • homologue covers homology with respect to similarity of structure and/or similarity of function providing the resultant promoter sequence has the ability to allow for expression of a GOI, such as a nucleotide sequence according to the present invention.
  • sequence homology i.e. similarity
  • sequence homology preferably there is more than 80% homology, more preferably at least 85% homology, more preferably at least 90% homology, even more preferably at least 95 % homology, more preferably at least 98% homology.
  • sequence homology i.e. similarity
  • sequence homology preferably there is more than 80% homology, more preferably at least 85% homology, more preferably at least 90% homology, even more preferably at least 95 % homology, more preferably at least 98% homology.
  • allelic variations of the sequences are also synonymous with allelic variations of the sequences.
  • the intron sequence of the present invention can be any one or all of the intron sequences of the present invention, including partial sequences thereof, provided that if partial sense sequences are used the partial sequences affect enzymatic activity. Suitable examples of partial sequences include sequences that are shorter than any one of the full sense sequences shown as SEQ. ID. No. 38 but which comprise nucleotides that are adjacent the respective exon or exons.
  • the nucleotide sequences of the present invention may comprise one or more sense or antisense exon sequences of the class A or class B SBE gene (but not sense exon sequences naturally associated with the intron sequence), including complete or partial sequences thereof, providing the nucleotide sequences can affect SBE activity, preferably wherein the nucleotide sequences reduce or eliminate SBE activity.
  • the nucleotide sequence of the second aspect of the present invention does not comprise sense exon sequences.
  • vector includes an expression vector and a transformation vector.
  • expression vector means a construct capable of in vivo or in vitro expression.
  • transformation vector means a construct capable of being transferred from one species to another - such as from an E.Coli plasmid to a fungus or a plant cell, or from an Agrobacterium to a plant cell.
  • construct which is synonymous with terms such as “conjugate”, “cassette” and “hybrid” - in relation to the sense nucleotide sequence aspect of the present invention includes the nucleotide sequence according to the present invention directly or indirectly attached to a promoter.
  • An example of an indirect attachment is the provision of a suitable spacer group such as an intron sequence, such as the Shi -intron or the ADH intron, intermediate the promoter and the nucleotide sequence of the present invention.
  • fused in relation to the present invention which includes direct or indirect attachment. The terms do not cover the natural combination of the wild type SBE gene when associated with the wild type SBE gene promoter in their natural environment.
  • the construct may even contain or express a marker which allows for the selection of the genetic construct in, for example, a plant cell into which it has been transferred.
  • a marker which allows for the selection of the genetic construct in, for example, a plant cell into which it has been transferred.
  • Various markers exist which may be used in, for example, plants - such as mannose.
  • Other examples of markers include those that provide for antibiotic resistance - e.g. resistance to G418, hygromycin, bleomycin, kanamycin and gentamycin.
  • the construct of the present invention preferably comprises a promoter.
  • promoter is used in the normal sense of the art, e.g. an RNA polymerase binding site in the Jacob-Monod theory of gene expression.
  • suitable promoters are those that can direct efficient expression of the nucleotide sequence of the present invention and/or in a specific type of cell.
  • tissue specific promoters are disclosed in WO 92/11375.
  • the promoter could additionally include conserved regions such as a Pribnow Box or a TATA box.
  • the promoters may even contain other sequences to affect (such as to maintain, enhance, decrease) the levels of expression of the nucleotide sequence of the present invention.
  • sequences include the S/zi-intron or an ADH intron.
  • Other sequences include inducible elements - such as temperature, chemical, light or stress inducible elements.
  • suitable elements to enhance transcription or translation may be present.
  • An example of the latter element is the TMV 5' leader sequence (see Sleat Gene 217 [1987] 217-225; and Dawson Plant Mol. Biol. 23 [1993] 97).
  • the construct and/or the vector of the present invention may include a transcriptional initiation region which may provide for regulated or constitutive expression.
  • Any suitable promoter may be used for the transcriptional initiation region, such as a tissue specific promoter.
  • the promoter is the patatin promoter or the E35S promoter.
  • the promoter is the SBE promoter.
  • the promoter can be one that affects expression of the nucleotide sequence in any one or more of seed, tuber, stem, sprout, root and leaf tissues, preferably tuber.
  • the promoter for the nucleotide sequence of the present invention can be the ⁇ -Amy 1 promoter (otherwise known as the Amy 1 promoter, the Amy 637 promoter or the ⁇ -Amy 637 promoter) as described in our co-pending UK patent application No. 9421292.5 filed 21 October 1994.
  • the promoter for the nucleotide sequence of the present invention can be the ⁇ -Amy 3 promoter (otherwise known as the Amy 3 promoter, the Amy 351 promoter or the ⁇ -Amy 351 promoter) as described in our co-pending UK patent application No. 9421286.7 filed 21 October 1994.
  • the present invention also encompasses the use of a promoter to express a nucleotide sequence according to the present invention, wherein a part of the promoter is inactivated but wherein the promoter can still function as a promoter. Partial inactivation of a promoter in some instances is advantageous. In particular, with the Amy 351 promoter mentioned earlier it is possible to inactivate a part of it so that the partially inactivated promoter expresses the nucleotide sequence of the present invention in a more specific manner such as in just one specific tissue type or organ.
  • the term "inactivated” means partial inactivation in the sense that the expression pattern of the promoter is modified but wherein the partially inactivated promoter still functions as a promoter.
  • the modified promoter is capable of expressing a gene coding for the enzyme of the present invention in at least one (but not all) specific tissue of the original promoter.
  • partial inactivation include altering the folding pattern of the promoter sequence, or binding species to parts of the nucleotide sequence, so that a part of the nucleotide sequence is not recognised by, for example, RNA polymerase.
  • Another, and preferable, way of partially inactivating the promoter is to truncate it to form fragments thereof. Another way would be to mutate at least a part of the sequence so that the RNA polymerase can not bind to that part or another part.
  • Another modification is to mutate the binding sites for regulatory proteins for example the CreA protein known from filamentous fungi to exert carbon catabolite repression, and thus abolish the catabolite repression of the native promoter.
  • the construct and/or the vector of the present invention may include a transcriptional termination region.
  • the nucleotide according to the present invention can be expressed in combination (but not necessarily at the same time) with an additional construct.
  • the present invention also provides a combination of constructs comprising a first construct comprising the nucleotide sequence according to the present invention operatively linked to a first promoter; and a second construct comprising a GOI operatively linked to a second promoter (which need not be the same as the first promoter).
  • the combination of constructs may be present in the same vector, plasmid, cells, tissue, organ or organism.
  • This aspect of the present invention also covers methods of expressing the same, preferably in specific cells or tissues, such as expression in just a specific cell or tissue, of an organism, typically a plant.
  • the second construct does not cover the natural combination of the gene coding for an enzyme ordinarily associated with the wild type gene promoter when they are both in their natural environment.
  • An example of a suitable combination would be a first construct comprising the nucleotide sequence of the present invention and a promoter, such as the promoter of the present invention, and a second construct comprising a promoter, such as the promoter of the present invention, and a GOI wherein the GOI codes for another starch branching enzyme either in sense or antisense orientation.
  • GOI with reference to the promoter aspect of the present invention or the combination aspect of the present invention means any gene of interest, which need not necessarily code for a protein or an enzyme - as is explained later.
  • a GOI can be any nucleotide sequence that is either foreign or natural to the organism in question, for example a plant.
  • Typical examples of a GOI include genes encoding for other proteins or enzymes that modify metabolic and catabolic processes.
  • the GOI may code for an agent for introducing or increasing pathogen resistance.
  • the GOI may even be an antisense construct for modifying the expression of natural transcripts present in the relevant tissues.
  • An example of such a GOI is the nucleotide sequence according to the present invention.
  • the GOI may even code for a protein that is non-natural to the host organism - e.g. a plant.
  • the GOI may code for a compound that is of benefit to animals or humans.
  • the GOI could code for a pharmaceutically active protein or enzyme such as any one of the therapeutic compounds insulin, interferon, human serum albumin, human growth factor and blood clotting factors.
  • the GOI may even code for a protein giving additional nutritional value to a food or feed or crop.
  • Typical examples include plant proteins that can inhibit the formation of anti-nutritive factors and plant proteins that have a more desirable amino acid composition (e.g. a higher lysine content than a non- transgenic plant).
  • the GOI may even code for an enzyme that can be used in food processing such as xylanases and ⁇ -galactosidase.
  • the GOI can be a gene encoding for any one of a pest toxin, an antisense transcript such as that for ⁇ -amylase, a protease or a glucanase.
  • the GOI can be a nucleotide sequence according to the present invention.
  • the GOI can be the nucleotide sequence coding for the arabinofuranosidase enzyme which is the subject of our co-pending UK patent application 9505479.7.
  • the GOI can be the nucleotide sequence coding for the glucanase enzyme which is the subject of our co-pending UK patent application 9505475.5.
  • the GOI can be the nucleotide sequence coding for the ⁇ -amylase enzyme which is the subject of our co-pending UK patent application 9413439.2.
  • the GOI can be the nucleotide sequence coding for the ⁇ - amylase enzyme which is the subject of our co-pending UK patent application 9421290.9.
  • the GOI can be any of the nucleotide sequences coding for the ⁇ -glucan lyase enzyme which are described in our co-pending PCT patent application PCT/EP94/03397.
  • the GOI can even be a nucleotide sequence according to the present invention but when operatively linked to a different promoter.
  • the GOI could include a sequence that codes for one or more of a xylanase, an arabinase, an acetyl esterase, a rhamnogalacturonase, a glucanase, a pectinase, a branching enzyme or another carbohydrate modifying enzyme or proteinase.
  • the GOI may be a sequence that is antisense to any of those sequences.
  • the present invention provides a mechanism for selectively affecting a particular enzymatic activity.
  • a genomic nucleotide sequence coding for a genomic protein or enzyme by expressing a sense intron construct for that particular genomic protein or enzyme and (e.g. at the same time) expressing a recombinant version of that enzyme or protein - in other words the GOI is a recombinant nucleotide sequence coding for the genomic enzyme or protein.
  • This application allows expression of desired recombinant enzymes and proteins in the absence of (or reduced levels of) respective genomic enzymes and proteins.
  • the desired recombinant enzymes and proteins can be easily separated and purified from the host organism.
  • This particular aspect of the present invention is very advantageous over the prior art methods which, for example, rely on the use of anti- sense exon expression which methods also affect expression of the recombinant enzyme.
  • a further aspect of the present invention relates to a method of expressing a recombinant protein or enzyme in a host organism comprising expressing a nucleotide sequence coding for the recombinant protein or enzyme; and expressing a further nucleotide sequence wherein the further nucleotide sequence codes, partially or completely, for an intron in a sense orientation; wherein the intron is an intron normally associated with the genomic gene encoding a protein or an enzyme corresponding to the recombinant protein or enzyme; and wherein the further nucleotide sequence does not contain a sequence that is sense to an exon sequence normally associated with the intron. Additional aspects cover the combination of those nucleotide sequences including their incorporation in constructs, vectors, cells, tissues and transgenic organisms.
  • the present invention also relates to a combination of nucleotide sequences comprising a first nucleotide sequence coding for a recombinant enzyme; and a second nucleotide sequence which corresponds to an intron in a sense orientation; wherein the intron is an intron that is associated with a genomic gene encoding the enzyme corresponding to the recombinant enzyme; and wherein the second nucleotide sequence does not contain a sequence that is sense to an exon sequence normally associated with the intron.
  • the GOI may even code for one or more introns but in an antisense orientation, such as any one or more of the antisense intron sequences presented in the attached sequence listings.
  • the present invention also covers the expression of for example a sense intron (e.g. SEQ. I.D. No. 38) in combination with for example an antisense intron which preferably is not complementary to the sense intron sequence (e.g. SEQ. I.D. No. 16).
  • cell include cell, tissue and organ per se and when within an organism.
  • organism in relation to the present invention includes any organism that could comprise the nucleotide sequence according to the present invention and/or wherein the nucleotide sequence according to the present invention can be expressed when present in the organism.
  • the organism is a starch producing organism such as any one of a plant, algae, fungi, yeast and bacteria, as well as cell lines thereof.
  • the organism is a plant.
  • starch producing organism includes any organism that can biosynthesise starch.
  • the starch producing organism is a plant.
  • plant as used herein includes any suitable angiosperm, gymnosperm, monocotyledon and dicotyledon.
  • suitable plants include vegetables such as potatoes; cereals such as wheat, maize, and barley; fruit; trees; flowers; and other plant crops.
  • the term means "potato”.
  • transgenic organism in relation to the present invention includes any organism that comprises the nucleotide sequence according to the present invention and/or products obtained therefrom, and/or wherein the nucleotide sequence according to the present invention can be expressed within the organism.
  • the nucleotide sequence of the present invention is incorporated in the genome of the organism.
  • the transgenic organism is a plant, more preferably a potato.
  • prokaryotic or eukaryotic organisms examples include E. coli and Bacillus subtilis. Teachings on the transformation of prokaryotic hosts is well documented in the art. for example see Sambrook et al (Sambrook et al. in Molecular Cloning: A Laboratory Manual, 2nd edition, 1989, Cold Spring Harbor Laboratory Press).
  • the basic principle in the construction of genetically modified plants is to insert genetic information in the plant genome so as to obtain a stable maintenance of the inserted genetic material.
  • the present invention relates to a vector system which carries a nucleotide sequence or construct according to the present invention and which is capable of introducing the nucleotide sequence or construct into the genome of an organism, such as a plant.
  • the vector system may comprise one vector, but it can comprise two vectors. In the case of two vectors, the vector system is normally referred to as a binary vector system.
  • Binary vector systems are described in further detail in Gynheung An et al. (1980), Binary Vectors, Plant Molecular Biology Manual A3, 1-19.
  • Ti plasmids from Agrobacterium tumefaciens or a Ri plasmid from Agrobacterium rhizogenes An et al. (1986), Plant Physiol. 81, 301-305 and Butcher D.N. et al. (1980), Tissue Culture Methods for Plant Pathologists, eds.: D.S. Ingrams and J.P. Helgeson, 203-208.
  • Ti and Ri plasmids have been constructed which are suitable for the construction of the plant or plant cell constructs described above.
  • a non-limiting example of such a Ti plasmid is pGV3850.
  • the nucleotide sequence or construct of the present invention should preferably be inserted into the Ti-plasmid between the terminal sequences of the T-DNA or adjacent a T-DNA sequence so as to avoid disruption of the sequences immediately surrounding the T-DNA borders, as at least one of these regions appears to be essential for insertion of modified T-DNA into the plant genome.
  • the vector system of the present invention is preferably one which contains the sequences necessary to infect the plant (e.g. the vir region) and at least one border part of a T-DNA sequence, the border part being located on the same vector as the genetic construct.
  • the vector system is preferably an Agrobacterium tumefaciens Ti-plasmid or an Agrobacterium rhizogenes Ri-plasmid or a derivative thereof.
  • these plasmids are well-known and widely employed in the construction of transgenic plants, many vector systems exist which are based on these plasmids or derivatives thereof.
  • the nucleotide sequence or construct of the present invention may be first constructed in a microorganism in which the vector can replicate and which is easy to manipulate before insertion into the plant.
  • An example of a useful microorganism is E. coli, but other microorganisms having the above properties may be used.
  • a vector of a vector system as defined above When a vector of a vector system as defined above has been constructed in E. coli, it is transferred, if necessary, into a suitable Agrobacterium strain, e.g. Agrobacterium tumefaciens.
  • the Ti-plasmid harbouring the nucleotide sequence or construct of the present invention is thus preferably transferred into a suitable Agrobacterium strain, e.g. A. tumefaciens, so as to obtain an Agrobacterium cell harbouring the promoter or nucleotide sequence or construct of the present invention, which DNA is subsequently transferred into the plant cell to be modified.
  • T-DNA for the transformation of plant cells, at least the right boundary and often however the right and the left boundary of the Ti- and Ri-plasmid T-DNA, as flanking areas of the introduced genes, can be connected.
  • T-DNA for the transformation of plant cells has been intensively studied and is described in ⁇ P-A-120516; Hoekema, in: The Binary Plant Vector System Offset- drukkerij Kanters B.B., Alblasserdam, 1985, Chapter V; Fraley, et al., Cut. Rev. Plant Sci., 4:1-46; and An et al., EMBO J. (1985) 4:277-284.
  • a plant to be infected is wounded, e.g. by cutting the plant with a razor blade or puncturing the plant with a needle or rubbing the plant with an abrasive.
  • the wound is then inoculated with the Agrobacterium.
  • the inoculated plant or plant part is then grown on a suitable culture medium and allowed to develop into mature plants.
  • tissue culturing methods such as by culturing the cells in a suitable culture medium supplied with the necessary growth factors such as amino acids, plant hormones, vitamins, etc.
  • Regeneration of the transformed cells into genetically modified plants may be accomplished using known methods for the regeneration of plants from cell or tissue cultures, for example by selecting transformed shoots using an antibiotic and by subculturing the shoots on a medium containing the appropriate nutrients, plant hormones, etc.
  • cloning vectors which contain a replication system in E. coli and a marker which allows a selection of the transformed cells.
  • the vectors contain for example pBR 322, pUC series, M13 mp series, pACYC 184 etc.
  • the nucleotide or construct of the present invention can be introduced into a suitable restriction position in the vector.
  • the contained plasmid is then used for the transformation in E.coli.
  • the E.coli cells are cultivated in a suitable nutrient medium and then harvested and lysed.
  • the plasmid is then recovered.
  • sequence analysis there is generally used sequence analysis, restriction analysis, electrophoresis and further biochemical-molecular biological methods. After each manipulation, the used DNA sequence can be restricted and connected with the next DNA sequence. Each sequence can be cloned in the same or different plasmid.
  • nucleotide sequence or construct according to the present invention After the introduction of the nucleotide sequence or construct according to the present invention in the plants the presence and/or insertion of further DNA sequences may be necessary - such as to create combination systems as outlined above (e.g. an organism comprising a combination of constructs).
  • the present invention relates to affecting enzyme activity by expressing sense intron sequences.
  • the present invention relates to a promoter useful for the expression of those sense intron sequences.
  • NCIMB National Collections of Industrial and Marine Bacteria Limited
  • NCIMB 40754 (which refers to pBEA 11 as described herein);
  • NCIMB 40751 (which refers to ⁇ -SBE 3.2 as described herein), and
  • NCIMB 40752 (which refers to ⁇ -SBE 3.4 as described herein).
  • a highly preferred embodiment of the present invention therefore relates to a method of affecting enzymatic activity in a plant (or a cell, a tissue or an organ thereof) comprising expressing in the plant (or a cell, a tissue or an organ thereof) a nucleotide sequence wherein the nucleotide sequence codes, partially or completely, for an intron in a sense orientation; wherein the nucleotide sequence does not contain a sequence that is sense to an exon sequence normally associated with the intron; wherein starch branching enzyme activity is affected and/or the levels of amylopectin are affected and/or the composition of starch is changed; and wherein the intron nucleotide sequence is the sequence of intron 1 of class A SBE as set forth in SEQ.
  • sequence of introns of class A SBE other than intron 1 may be obtained by sequencing of, for example, potato class A SBE genomic DNA, isolatable by hybridisation screening of a genomic DNA library with class A SBE cDNA obtainable according to W096/34968 according to methods well known in the art and set forth, for example, in Sambrook et al. , Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, 1989.
  • Figure 1 is a schematic representation of the biosynthesis of amylose and amylopectin
  • Figure 2 which is a diagrammatic representation of the ⁇ -l-4-links and the ⁇ -1-6 links of amylopectin;
  • Figure 3 which is a diagrammatic representation of the exon-intron structure of a genomic SBE clone
  • Figure 4 which is a plasmid map of pPATAl, which is 3936 bp in size;
  • Figure 5 which is a plasmid map of pABE7, which is 5106 bp in size;
  • Figure 6 which is a plasmid map of pVictorlV Man, which is 7080 bp in size;
  • Figure 7 which is a plasmid map of pBEAll, which is 9.54 kb in size
  • Figure 8 which shows the full genomic nucleotide sequence for SBE including the promoter, exons and introns;
  • Figure 9 which is a plasmid map of pVictor5a, which is 9.12 kb in size;
  • Figure 10 which is a plasmid map of pBEP2, which is 10.32 kb in size;
  • Figure 11 which shows the positioning of intron 1 in the class A and class B SBE genes
  • Figures 1 and 2 were referred to above in the introductory description concerning starch in general.
  • Figure 3 is a diagrammatic representation of the exon-intron structure of a genomic SBE clone, the sequence of which is shown in Figure 8.
  • This clone which has about 11.5 k base pairs, comprises 14 exons and 13 introns.
  • the introns are numbered in increasing order from the 5 ' end to the 3 ' end and correspond to SEQ. I.D. No. s 1-13, respectively.
  • Their respective antisense intron sequences are shown as SEQ.I.D.No.s 15-27.
  • Figures 3 and 8 present information on the 11468 base pairs of a potato SBE gene.
  • the 5' region from nucleotides 1 to 2082 contain the promoter region of the SBE gene.
  • a TATA box candidate at nucleotide 2048 to 2051 is boxed.
  • the homology between a potato SBE cDNA clone (Poulsen & Kreiberg (1993) Plant Physiol 102: 1053- 1054) and the exon DNAs begin at 2083 bp and end at 9666 bp.
  • the homology between the cDNA and the exon DNA is indicated by nucleotides in upper case letters, while the translated amino acid sequences are shown in the single letter code below the exon DNA.
  • Figure 7 is a plasmid map of pBEA7, which is 9.54 k base pairs in size. Plasmid pBEA 11 comprises the first intron sequence of the potato SBE gene. This first intron sequence, which has 1177 base pairs, is shown in Figure 3 and lies between the first exon and the second exon.
  • ⁇ SBE 3.2 contains a 15 kb potato DNA insert and ⁇ SBE-3.4 contains a 13 kb potato DNA insert.
  • the resultant plasmids are called pGB3, pGBll, pGB15, pGB16 and pGB25 (see discussion below).
  • the respective inserts are then sequenced using the Pharmacia Autoread Sequencing Kit (Pharmacia, Uppsala) and a A.L.F. DNA sequencer (Pharmacia, Uppsala). In total, a stretch of 11.5 kb of the SBE gene is sequenced.
  • pGB25 contains the sequences from 1 bp to 836 bp
  • pGB15 contains the sequences from 735 bp to 2580 bp
  • pGB16 contains the sequences from 2580 bp to 5093 bp
  • pGBll contains the sequences from 3348 bp to 7975 bp
  • pGB3 contains the sequences from 7533 bp to 11468 bp.
  • pGB3 is constructed by insertion of a 4 kb EcoRl fragment isolated from ⁇ SBE 3.2 into the EcoRl site of pBluescript II SK (+).
  • pGBll is constructed by insertion of a 4.7 kb Xhol fragment isolated from ⁇ SBE 3.4 into the Xhol site of pBluescript II SK (+).
  • pGB15 is constructed by insertion of a 1.7 kb Spel fragment isolated from ⁇ SBE 3.4 into the Spel site of pBluescript II SK (+).
  • pGB16 is constructed by insertion of a 2.5 kb Spel fragment isolated from ⁇ SBE 3.4 into the Spel site of pBluescript II SK (+).
  • the PCR fragment is digested with BamHl and EcoRl, and inserted in pBluescript II SK (+) digested with the same restriction enzymes.
  • the SBE intron 1 is amplified by PCR using the oligonucleotides
  • the PCR product is digested with BamHl and inserted in a sense orientation in the BamHl site of plasmid pPATAl (described in WO 94/24292) between the patatin promoter and the 35S terminator.
  • This construction, pABE7 is digested with Kpnl, and the 2.4 kb "patatin promoter-SBE intron 1- 35S terminator" Kpnl fragment is isolated and inserted in the Kpnl site of the plant transformation vector pVictorlV Man yielding plasmid pBEAll .
  • the 2122 bp intron 1 sequence of the potato SBEII gene (see SEQ. ID. No. 38) is amplified by PCR from a genomic SBEII subclone using the primers 5' - CGG GAT CCC GTA TGT CTC ACT GTG TTT GTG GC - 3' (SEQ. ID. No. 34) and 5' - CGG GAT CCC CCT ACA TAC ATA TAT CAG ATT AG - 3' (SEQ. ID. No. 35).
  • the PCR product is digested with BamHl and inserted in sense orientation after a patatin promoter in the BamHl site of a plant transformation vector in which the NPTII gene is used as selectable marker (see figure 13).
  • the 2122 bp intron 1 sequence of the potato SBEII gene (SEQ. ID. No. 38) is amplified by PCR from a genomic SBEII subclone using the primers 5' - CGG GAT CCC GTA TGT CTC ACT GTG TTT GTG GC - 3' (SEQ. ID. No. 34) and 5' - CGG GAT CCC CCT ACA TAC ATA TAT CAG ATT AG - 3' (SEQ. ID. No. 35).
  • the PCR product is digested with BamHl and inserted in sense orientation after a patatin promoter in the BamHl site of a plant transformation vector in which the manA gene is used as selectable marker (see figure 14).
  • Axenic stock cultures Shoot cultures of Solanum tuberosum 'Bintje' and 'Dianella' are maintained on a substrate (LS) of a formula according to Linsmaier, E.U. and Skoog, F. (1965), Physiol.
  • Plant. 18 100-127, in addition containing 2 ⁇ M silver thiosulphate at 25°C and 16 h light/8 h dark.
  • the cultures are subcultured after approximately 40 days. Leaves are then cut off the shoots and cut into nodal segments (approximately 0.8 cm) each containing one node.
  • the Agrobacterium are grown overnight in YMB-substrate (di-potassium hydrogen phosphate, trihydrate (0.66 g/1); magnesium sulphate, heptahydrate (0.20 g/1); sodium chloride (0.10 g/1); mannitol (10.0 g/1); and yeast extract (0.40 g/1)) containing appropriate antibiotics (corresponding to the resistance gene of the Agrobacterium strain) to an optical density at 660 nm (OD-660) of approximately 0.8, centrifuged and resuspended in the LS-substrate to an OD-660 of 0.5.
  • YMB-substrate di-potassium hydrogen phosphate, trihydrate (0.66 g/1); magnesium sulphate, heptahydrate (0.20 g/1); sodium chloride (0.10 g/1); mannitol (10.0 g/1); and yeast extract (0.40 g/1)
  • appropriate antibiotics corresponding to the resistance gene of the Agrobacterium strain
  • the segments are left in the suspension of Agrobacterium for 30 minutes and then the excess of bacteria are removed by blotting the segments on sterile filter paper.
  • the shoot segments are co-cultured with bacteria for 48 hours directly on LS- substrate containing agar (8.0 g/1), 2,4-dichlorophenoxyacetic acid (2.0 mg/1) and trans- zeatin (0.5 mg/1).
  • the substrate and also the explants are covered with sterile filter papers, and the petri dishes are placed at 25°C and 16 h light/ 8 dark.
  • the segments are transferred to containers containing liquid LS-substrate containing 800 mg/1 carbenicillin.
  • the containers are gently shaken and by this procedure the major part of the Agrobacterium is either washed off the segments and/or killed.
  • the segments are transferred to plates containing the LS-substrate, agar (8 g/1), trans-zeatin (1-5 mg/1), gibberellic acid (0.1 mg/1), carbenicillin (800 mg/1), and kanamycin sulphate (50-100 mg/1) or phosphinotricin (1-5 mg/1) or mannose (5 g/1) depending on the vector construction used.
  • the segments are sub-cultured to fresh substrate each 3-4 weeks. In 3 to 4 weeks, shoots develop from the segments and the formation of new shoots continued for 3-4 months.
  • Rooting of regenerated shoots The regenerated shoots are transferred to rooting substrate composed of LS- substrate, agar (8 g/1) and carbenicillin (800 mg/1).
  • the transgenic genotype of the regenerated shoot are verified by testing the rooting ability on the above mentioned substrates containing kanamycin sulphate (200 mg/1), by performing NPTII assays (Radke, S. E. et al, Theor. Appl. Genet. (1988), 75: 685-694) or by performing PCR analysis according to Wang et al (1993, NAR 21 pp 4153-4154). Plants which are not positive in any of these assays are discarded or used as controls.
  • the transgenic plants could be verified by performing a GUS assay on the co-introduced ⁇ - glucuronidase gene according to Hodal, L. et al. (PI. Sci. (1992), 87: 115-122).
  • the newly rooted plants (height approx. 2-3 cms) are transplanted from rooting substrate to soil and placed in a growth chamber (21°C, 16 hour light 200-400uE/m7sec). When the plants are well established they are transferred to the greenhouse, where they are grown until tubers had developed and the upper part of the plants are senescing.
  • the potatoes are harvested after about 3 months and then analysed.
  • the SBE expression in the transgenic potato lines are measured using the SBE assays described by Blennow and Johansson (Phytochemistry (1991) 30:437-444) and by standard Western procedures using antibodies directed against class A and class B potato SBE.
  • STARCH ANALYSIS Starch is isolated from potato tubers and analysed for the amylose:amylopectin ratio (Hovenkamp-Hermelink et al. (1988) Potato Research 31:241-246). In addition, the chain length distribution of amylopectin is determined by analysis of isoamylase digested starch on a Dionex HPAEC. The number of reducing ends in isoamylase digested starch is determined by the method described by N. Nelson (1944) J. Biol. Chem. 153:375-380. The results revealed that there is a reduction in the level of synthesis of SBE and/or the level of activity of SBE and/or the composition of starch SBE in the transgenic plants.
  • An SBE promoter fragment is amplified from ⁇ -SBE 3.4 using primers: 5 ' CCA TCG ATA CTT TAA GTG ATT TGA TGG C 3'
  • Potatoes from potato plants transformed with pBEAl 1 are cut in small pieces and homogenised in extraction buffer (50 mM Tris-HCl pH 7.5, Sodium-dithionite (0.1 g/1), and 2 mM DTT) using a Ultra-Turax homogenizer; 1 g of Dowex xl. is added pr. 10 g of tuber.
  • the crude homogenate is filtered through a miracloth filter and centrifuged at 4°C for 10 minutes at 24.700 g. The supernatant is used for starch branching enzyme assays.
  • the starch branching enzyme assays are carried out at 25 °C in a volume of 400 ⁇ l composed of 0.1 M Na citrate buffer pH 7.0, 0.75 mg/ml amylose, 5 mg/ml bovine serum albumin and the potato extract. At 0, 15 30 and 60 minutes aliqouts of 50 ⁇ l are removed from the reaction into 20 ⁇ l 3 N HCl. 1 ml of iodine solution is added and the decrease in absorbance at 620 nm is measured with an ELISA spectrophotometer.
  • the starch branching enzyme (SBE) levels in tuber extracts are measured from 24 transgenic Dianella potato plants transformed with plasmid pBEAll, pSS15 and pSS16.
  • the above-mentioned examples relate to the isolation and sequencing of a gene for potato SBE.
  • the examples further demonstrate that it is possible to prepare SBE intron constructs.
  • These SBE intron constructs can be introduced into plants, such as potato plants. After introduction, a reduction in the level of synthesis of SBE and/or the level of activity of SBE and/or the composition of starch in plants can be achieved.
  • the expressed sense intron nucleotide sequence according to the present invention affects enzymatic activity via co-suppression and/or trans-activation. Reviews of these mechanisms has been published by Finnegan and McElroy (1994 Biotechnology 12 pp 883 - 887) and Matzke and Matzke (1995 TIG 11 No. 1 pp 1 - 3). By these mechanisms, it is believed that the sense introns of the present invention reduce the level of plant enzyme activity (in particular SBE activity), which in turn for SBE activity is believed to influence the amylose: amylopectin ratio and thus the branching pattern of amylopectin.
  • the present invention provides a method wherein it is possible to manipulate the starch composition in plants, or tissues or cells thereof, such as potato tubers, by reducing the level of SBE activity by using sense intron sequences.
  • the present invention therefore relates to the surprising use of SBE class A sense intron sequences in a method to affect class A SBE activity in plants.
  • SEQ.I.D. No. 13 represent sense intron sequences (genomic DNA); SEQ.I.D. No. 14 represents the SBE promoter sequence (genomic sequence); SEQ.I.D. No. 15 - SEQ.I.D. No. 27 represent antisense intron sequences; and SEQ. I.D. No. 28 represents the sequence complementary to the SBE promoter sequence - i.e. the SBE promoter sequence in antisense orientation.
  • SEQ. I.D. No. 29 see Figures 3 and 8 which highlight particular gene features.
  • SEQ. ID. No. 30 to 37 show primers used in the methods set forth above.
  • SEQ. ID. No. 38 represents the nucleotide sequence of intron 1 of the class A potato SBE gene.
  • MOLECULE TYPE DNA (genomic)
  • AGTGTATAAA ATTCAAAAAT TGAGAGATGG AGGGGGGGTG GGGGAAGACA ATATTTAGAA 240
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • ATAGCTTCCT TAATATTAAA TTCATGATAC TTTTGTTGAG ATTTAGCAGT TTTTTCTTGT 480
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • GTTTGTCTGT TTCTATTGCA TTTTAAGGTT CATATAGGTT AGCCACGGAA AATCTCACTC 60
  • MOLECULE TYPE DNA (genomic)
  • HYPOTHETICAL NO
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • AAAAGGATGC CAAAAAAATT CTTCTCTATC CTCTTTTTCC CTAAACCAGT GCATGTAGCT 240
  • AAAAAGTCCA AAAAGAAGTA ACAGAAGTGA AAGCAACATG TGTAGCTAAA GCGACCCAAC 540
  • MOLECULE TYPE DNA (genomic)
  • AAAATAAATT ATTTTTTGAC ATTCTAAAAC TTTAAGCAGA ATAAATAGTT TATCAATTAT 1440
  • TTTAGCCTAA CCAACGAATA TTTGTAAACT CACAACTTGA TTAAAAGGGA TTTACAACAA 1620
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • CTGCATTTCA TCATGAGGGG GAGGAAAGAC GGAGAAATAT AGATATCAGA TTTAGACCAT 60
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • TCTAATCCCA CTTGAAATGA GAGTTATTTT AATATCGACC GTTAATTACC ATTTTATTAT 1500 TAAATCTGCA ACTACAGTCA ACTACACCAA TGATTTTGCT GATGCCAACT CATAATATAA 1560
  • CTGTGTACTT GTCTTTTCCT TGTAATAATG TATGTATGAT AATAATAATA AGAGAACAAA 1860
  • MOLECULE TYPE DNA (genomic)
  • AAAATAAATT ATTTTTTGAC ATTCTAAAAC TTTAAGCAGA ATAAATAGTT TATCAATTAT 1440
  • TTTAGCCTAA CCAACGAATA TTTGTAAACT CACAACTTGA TTAAAAGGGA TTTACAACAA 1620
  • TTCTGTTCGA AATAGCTTCC TTAATATTAA ATTCATGATA CTTTTGTTGA GATTTAGCAG 4500
  • TCTTTTTCAA TATCCCTCTT ATTTGGAGGT AATTTTTCTC ATCTATTCAC TTTTAGCTTC 6660 TAACCACAGA TGATCCATTT TTTCACAATG GCCTTGGGAG GAGAGGGGTA CCTCAATTTC 6720
  • ACAAATGTAG ACGCCAGTGG AACCTCGCGG ATAGCGAACA CTTGAGATAC AAGGTTCAAG 7140
  • CTTTGTCTTC ATGCTGACAT ACAATCTGTT CTCATGACAG ACTGGTC TG ATGTTGACCA 8340
  • MOLECULE TYPE other nucleic acid
  • DESCRIPTION: /desc "Synthetic DNA Primer"
  • MOLECULE TYPE other nucleic acid
  • DESCRIPTION: /desc "Synthetic DNA Primer"
  • MOLECULE TYPE DNA (genomic)
  • AAAAGTTTTT TGATATACTT AAAAAATTGT CACACAGAAG AAAGAGTTTT TTACCATTAC 1860 TTAAGCTAGA TGGGACTGTT TGATTCTTAG ACCAAATAAT GAACCTTTTT GTTCTCTTAA 1920

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

L'invention concerne une méthode d'inhibition de l'expression d'un gène. Cette méthode, laquelle affecte l'activité enzymatique dans un végétal, consiste à exprimer dans un végétal (ou une cellule, un tissu ou bien un organe de celui-ci) une séquence nucléotidique codant partiellement ou totalement pour un intron de l'enzyme ramifiante de l'amidon de classe A dans une orientation sens, cette séquence nucléotidique ne contenant pas de séquence qui soit sens vis-à-vis d'une séquence d'exon normalement associée avec l'intron.
EP98904329A 1997-02-21 1998-02-23 Inhibition de l'expression de l'enzyme ramifiante de l'amidon par un intron sens Withdrawn EP1007708A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9703672.7A GB9703672D0 (en) 1997-02-21 1997-02-21 Inhibition of gene expression
GB9703672 1997-02-21
GB9706075 1997-03-24
GBGB9706075.0A GB9706075D0 (en) 1997-03-24 1997-03-24 Inhibition of gene expession
PCT/IB1998/000295 WO1998037214A1 (fr) 1997-02-21 1998-02-23 Inhibition de l'expression de l'enzyme ramifiante de l'amidon par un intron sens

Publications (1)

Publication Number Publication Date
EP1007708A1 true EP1007708A1 (fr) 2000-06-14

Family

ID=26311046

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98904329A Withdrawn EP1007708A1 (fr) 1997-02-21 1998-02-23 Inhibition de l'expression de l'enzyme ramifiante de l'amidon par un intron sens

Country Status (8)

Country Link
EP (1) EP1007708A1 (fr)
JP (1) JP2001512972A (fr)
CN (1) CN1248293A (fr)
AU (1) AU738311B2 (fr)
BR (1) BR9808648A (fr)
CA (1) CA2280210A1 (fr)
NZ (1) NZ336607A (fr)
WO (1) WO1998037214A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2826021B1 (fr) * 2001-06-13 2004-12-31 Centre Nat Rech Scient Procede de detection et d'identification de la presence de matieres biologiques provenant de poissons, et oligonucleotides pour sa mise en oeuvre
ATE405653T1 (de) 2002-12-19 2008-09-15 Bayer Cropscience Ag Pflanzenzellen und pflanzen, die eine stärke mit erhöhter endviskosität synthetisieren
FR2858631A1 (fr) * 2004-09-24 2005-02-11 Centre Nat Rech Scient Procede de detection et d'identification de la presence de matieres biologiques provenant de poissons, et oligonucleotides pour sa mise en oeuvre
EP1707632A1 (fr) 2005-04-01 2006-10-04 Bayer CropScience GmbH Amidon de pomme de terre cireux phosphorylé
WO2013053729A1 (fr) 2011-10-12 2013-04-18 Bayer Cropscience Ag Plantes ayant une activité diminuée d'une enzyme de déphosphorylation de l'amidon
BR112014008723A2 (pt) 2011-10-12 2019-09-24 Bayer Cropscience Ag plantas com diminuição da atividade de uma enzima de desforilação de àmido
CN104017829A (zh) * 2011-12-06 2014-09-03 中国科学院上海生命科学研究院 提高植物直链淀粉含量的方法
EA201892624A1 (ru) 2016-05-26 2019-06-28 Нунхемс Б.В. Растения, дающие бессемянные плоды
WO2019238832A1 (fr) 2018-06-15 2019-12-19 Nunhems B.V. Plantes à pastèques sans pépins comprenant des modifications dans un gène transporteur abc

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034323A (en) * 1989-03-30 1991-07-23 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
EP0575518A1 (fr) * 1991-03-06 1993-12-29 Board Of Regents, The University Of Texas System Procedes et compositions d'inhibition selective de l'expression de genes
EP0826061B1 (fr) * 1995-05-05 2007-07-04 National Starch and Chemical Investment Holding Corporation Ameliorations apportees a une composition a base d'amidon de plante
GB9514437D0 (en) * 1995-07-14 1995-09-13 Danisco Inhibition of gene expression
GB9514435D0 (en) * 1995-07-14 1995-09-13 Danisco Inhibition of gene expression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9837214A1 *

Also Published As

Publication number Publication date
WO1998037214A1 (fr) 1998-08-27
CA2280210A1 (fr) 1998-08-27
AU738311B2 (en) 2001-09-13
BR9808648A (pt) 2000-05-23
JP2001512972A (ja) 2001-08-28
CN1248293A (zh) 2000-03-22
NZ336607A (en) 2001-06-29
AU6225998A (en) 1998-09-09

Similar Documents

Publication Publication Date Title
AU738272B2 (en) Antisense intron inhibition of starch branching enzyme expression
US6232122B1 (en) Inhibition of gene expression
US6147279A (en) Inhibition of gene expression
MXPA98000500A (en) Inhibition of the expression of ge
MXPA98000499A (en) Inhibition of the expression of ge
AU738311B2 (en) Sense intron inhibition of starch branching enzyme expression
AU739067B2 (en) Selection method for transgenic plants
MXPA99007795A (en) Sense intron inhibition of starch branching enzyme expression
MXPA99007796A (en) Antisense intron inhibition of starch branching enzyme expression
AU720418B2 (en) Modified plants and plant products
EP1105500B1 (fr) Methode de selection

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990823

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030829

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040109